BPC-157: No Controlled Human Trial on Record

How was the absence measured?

The claim that a compound has never been tested in people is a measurement, and it is worth exactly as much as the instrument behind it. Four names carry this molecule through the literature, and a search of any one of them alone understates the record: the abbreviated form, the descriptive form used in the pharmacology papers, the full name of the parent protein, and the development code the compound was assigned when a pharmaceutical company still held it.

Searched together in August 2026, those four names return 230 indexed papers, of which 55 carry the Humans subject heading. Filtered to the clinical-trial publication type, the same union returns zero; filtered to the randomized-controlled-trial publication type, it also returns zero ^[2].

The second number in that sentence is the one that makes the first number mean anything. A publication-type filter that has stopped matching returns zero for every substance in the database, and a dead filter is indistinguishable from a true absence by looking at the output. This census therefore ran a control term with a large and undisputed trial literature through the identical filter in the same session; it returned 8,904 records, and a deliberately invalid record identifier errored in the same run ^[2]. The instrument was answering. The answer was zero.

A zero under the trial filter is not the same as no human exposure, and the literature shows the difference. Three reports from a single Florida practice describe BPC-157 given to people: a retrospective telephone follow-up of 16 patients who had knee injections ^[7], a single-arm pilot in 12 women with interstitial cystitis ^[8], and an intravenous safety pilot in two adults who had received the infusion before ^[9]. None had a control group or blinding, and none is indexed as a clinical trial.

The reference below carries the query rather than a description of it, so the search can be repeated rather than trusted. That is the standard this index holds itself to, and it is the standard any claim about this compound's evidence should be held to elsewhere.

What about the 2025 intravenous pilot study?

The human report most often quoted against the zero is "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study", by Lee and Burgess, published in Alternative Therapies in Health and Medicine in 2025 ^[9]. It is a real study and worth describing exactly. It was approved by an institutional review board and run at a private clinic in Florida. Two adults took part, a man of 58 and a woman of 68, and both had received intravenous BPC-157 before the study began.

Each received an infusion on two consecutive days. The authors drew blood and took vital signs before and after, then asked about side effects at every visit. The blood work covered markers of heart, liver, kidney and thyroid function and blood glucose. They report no measurable change in those markers and no side effects, and their conclusion asks for further studies to confirm safety ^[9].

It is not counted above for two reasons. The first is mechanical: PubMed indexes the paper as a journal article, not under the clinical-trial publication type, so the census filter cannot return it. The second is substantive: two people, no comparison group and no blinding cannot establish safety, and two people who had already taken the infusion cannot show how a first exposure goes. The paper sits in the human column with the other two reports, as uncontrolled experience in 30 people, and not as a trial.

What do the 230 papers actually establish?

The literature is not empty; it is preclinical. It describes a synthetic pentadecapeptide corresponding to a fragment of Body Protection Compound, a protein identified in human gastric juice, and it attributes the compound's effects principally to promotion of angiogenesis and to modulation of growth-factor signaling ^[1]. The models are rodent models of tendon transection, ligament injury, and gastrointestinal damage ^[1].

Those mechanisms are described in animals and have not been established in humans ^[1]. That sentence is doing the real work of this page: a mechanism observed in a rat is a hypothesis about a person, and the step that converts one into the other is precisely the step this record does not contain. No product containing BPC-157 has completed the clinical development an approval requires ^[1].

The distinction matters more here than the volume of publication suggests. Two hundred and thirty papers is a substantial file, and a reader who encounters the number without the publication-type breakdown will reasonably conclude that the compound is well studied. It is well studied in animals. The human column holds three uncontrolled case series and 30 people, and no quantity of the first column fills the second.

Why does the regulatory record turn on the same gap?

The absence is not an academic observation; it is the substance of the agency's position. In September 2023 the FDA placed BPC-157 in Category 2 of its interim bulk drug substances list, the category reserved for substances presenting significant safety concerns, citing immunogenicity risk and impurity questions; that placement barred licensed pharmacies from compounding it ^[3].

In April 2026 the agency removed BPC-157 and eleven other peptides from Category 2 without adding them to Category 1, which ended an explicit prohibition and conferred no authorization. In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding the compound to the section 503A bulks list ^[4]. The margin is reported as 8–6 with one abstention by McDermott Will & Schulte and by LumaLex Law, whose separate accounts of the meeting agree substance by substance ^{[5, 6]}; the FDA has published no minutes, transcript or vote summary for it, so that figure is secondary and this review says so where it prints one. That vote is advisory, the FDA has issued no final rule, and no licensed United States pharmacy may lawfully compound BPC-157 today. The dated ledger sits on the monograph; the arithmetic of the whole meeting sits in the vote ledger.

What is a reader weighing without a controlled trial?

BPC-157 draws roughly 183,000 United States searches per month while no controlled human trial of it has been published. That distance between commercial visibility and published evidence is unusually wide even in this market, and it is worth naming plainly rather than hedging: a reader weighing this compound is weighing animal data and three small case series, and the decision that follows is made without a controlled human safety record.

The material offered for sale compounds the problem. Because no lawful compounding route exists, what is sold under the name is research-use-only chemical supply, produced and sold outside pharmacy licensure, prescriber oversight, and pharmaceutical quality standards; its identity, purity, and sterility are whatever the vendor asserts them to be. The research-only page sets out why removal from a prohibition list is not permission, and the glossary defines what the labeling posture does and does not mean.

Elsewhere in this index